Drug intelligence / Profile preview

hepatitis b vaccine recombinant (Merck & Co.)

Development stage: Approved
Lead developer: Merck
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Hepatitis B vaccine recombinant is a vaccine used to prevent infection caused by all known subtypes of hepatitis B virus (HBV). It contains hepatitis B surface antigen (HBsAg) produced by yeast cells into which the gene for HBsAg has been inserted. After administration, the vaccine stimulates the immune system to produce antibodies (anti-HBs) against the hepatitis B surface antigen, providing immunity against HBV infection.

Brand names: Engerix-BRecombivax HBHeplisav-BHbvaxproFendrixShanvac BElovac BGenevac BEuvax BPreHevbri
Other names: hepatitis b recombinant dna vaccinehepatitis b vaccine (recombinant)hep-b(eng)recombinant hepatitis b vaccine

Beyond the preview

Go deeper on hepatitis b vaccine recombinant (Merck & Co.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hepatitis b vaccine recombinant (Merck & Co.).

Explore the full profile